CCM
NVO

Compass Capital Management’s Novo Nordisk NVO Stock Holding History

Compass Capital Management’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-22,130
Closed -$343K – 58
2013
Q2 		$343K Buy
+22,130
New +$368K 0.08% 44

Other funds holding NVO

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SF
Sarofim Fayez Houston, Texas $20.5B AUM
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
TIM
Thornburg Investment Management Santa Fe, New Mexico $9.63B AUM 35.65% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Compass Capital Management's NVO Position: Q3 2013 in Review

Compass Capital Management sold out of Novo Nordisk (NVO) in Q3 2013, closing a stake of 22,130 shares — an estimated $343K sold.

Compass Capital Management first reported a position in NVO in Q2 2013 and held it in 1 quarter. The position peaked at $343K in Q2 2013. 425 funds tracked by Wall St. Rank hold NVO as of Q3 2013.

  • Compass Capital Management reported no remaining Novo Nordisk position as of Q3 2013 after selling out during the quarter.
  • Compass Capital Management sold 22,130 Novo Nordisk shares in Q3 2013, an estimated $343K.
  • Compass Capital Management first reported a position in Novo Nordisk in Q2 2013 and held it in 1 quarter.
  • Compass Capital Management's Novo Nordisk position peaked at $343K in Q2 2013.
  • 425 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2013.

Based on Compass Capital Management's 13F filing for Q3 2013, filed 24 Oct 2013.